In this letter the authors describe being able to identified a sustained community transmission of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Australia
The US Department of Health and Human Services (HHS) recently announced that it has asked for clinical trials of a vaccine targeted against the novel A(H3N2)v triple reassortment viruses infecting some people in the USA.
Influenza viruses pose a particular challenge for those designing vaccines for humans. Much of the protective immunity that humans have against these viruses following natural infection or vaccination is due to immunological recognition of the haemagglutinin (HA) surface glycoprotein.
The US initiative raises the question of whether there should be a similar initiative in Europe, for example in support of the E.U. Council Recommendation on Seasonal Influenza Immunization